Restoring immunity in the most vulnerable
Chemotherapy saves lives — but it can leave patients defenceless against infection.
Neutrophils are essential immune cells that protect against bacterial and fungal pathogens. During intensive chemotherapy, neutrophil numbers can fall to critically low levels, leaving patients highly vulnerable to serious infections.
NeutroGen is developing a ready-to-use transfusion therapy to instantly restore missing neutrophil defences until the patient’s own immune system recovers.
A new kind of
neutrophil transfusion
Unlike red blood cells and platelets, neutrophils cannot currently be replaced through a reliable, readily available transfusion product.
NeutroGen is developing allogeneic, lab-grown neutrophils that can be cryopreserved, stored and deployed when urgently needed.
Our therapy is designed to prevent and treat life-threatening infections during severe neutropenia, when antibiotics and supportive care fail.
Emerging from science.
Built for patients.
NeutroGen Therapeutics is translating research originating at the University of Bristol into a scalable cell therapy. Our multidisciplinary founding team combines expertise in neutrophil biology, cell therapy, manufacturing, business development and company building.
Beyond our first clinical use case in chemotherapy, our technology holds promise for reducing the infection burden associated with haematopoietic stem cell transplantation and T cell transfusion therapies, genetic diseases of the immune system and the global crisis of antibiotic resistance.
